Preview

Медицинский алфавит

Расширенный поиск

Коморбидная патология и Patient Reported Outcomes при псориатическом артрите: обзор литературы

https://doi.org/10.33667/2078-5631-2019-1-18(393)-34-38

Полный текст:

Аннотация

Псориатический артрит относится к группе спондилоартритов и характеризуется гетерогенностью клинических проявлений. Согласно эпидемиологическим исследованиям, пациенты с псориатическим артритом часто страдают от коморбидной патологии, что влияет на качество жизни, ответ на проводимую терапию и является основной причиной смертности. На сегодняшний день сохраняет актуальность изучение взаимного влияния особенностей течения псориатического артрита и развития коморбидной патологии, так как по сравнению с другими хроническими воспалительными артритами этот вопрос изучен недостаточно. Коморбидная патология включает сердечно‑сосудистые заболевания, сахарный диабет, ожирение, метаболический синдром, остеопороз, заболевания печени, воспалительные заболевания кишечника, депрессию и др. Своевременная диагностика и контроль сопутствующих заболеваний позволят снизить развитие их осложнений, а лучшее понимание ведения таких пациентов — обеспечить оптимальный клинический результат.

Об авторах

И. Ф. Файрушина
ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России
Россия

аспирант кафедры госпитальной терапии

г. Казань



Э. И. Мухаметшина
ФГАУ ВО «Казанский (Приволжский) федеральный университет»
Россия

зам. гл. врача по медицинскому обслуживанию сотрудников, медико-санитарная часть

г. Казань



Д. И. Абдулганиева
ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России
Россия

д. м. н., проф., зав. кафедрой госпитальной терапии

г. Казань



Список литературы

1. Российские клинические рекомендации. Ревматология / под ред. Е. Л. Насонова. — М.: ГЭОТАР-Медиа, 2017; 87.

2. Koolaee RM, Takeshita J, Ogdie A. Epydemiology and natural history of psoriatic arthritis: an update. Curr Derm Rep. 2013; 2: 66–76.

3. Т. В. Коротаева, Д. С. Новикова, Е. Ю. Логинова. Риск развития сердечно-сосудистых заболеваний у больных псориатическим артритом. Терапевтический архив. 2016; 88 (5): 102–106.

4. Feinstein AR. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis. 1970; 23: 455–468.

5. Schellevis FG, van Eijk JT, van den Lisdonk EH et. al. Implementing guidelines in general practice. Evaluation of process and outcome of care in chronic diseases. Int J Qual Health Care. 1994; 6: 257–266.

6. Schellevis FG, van der Velden J, van de Lisdonk E et al. Comorbidity of chronic diseases in general practice. J Clin Epidemiol. 1993; 46: 469–473.

7. A. Haddad, D. Zisman et al. Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Medical Journal. 2017; (8): 1.

8. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016; 37 (29): 2315–2381.

9. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004; 34 (3): 585–592.

10. Маркелова Е. И., Новикова Д. С., Коротаева Т. В. и др. Распространенность традиционных кардиоваскулярных факторов риска, субклинического атеросклероза сонных артерий, коронарного кальциноза у пациентов с ранним псориатическим артритом (исследование РЕМАРКА). Научно-практическая ревматология. 2018; 56 (2): 184–188.

11. Boehncke WH, Boehncke S, Tobin AM et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20: 303–307.

12. Tam L-S, Tomlinson B, Chu TT-W et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls — the role of inflammation. Rheumatology. 2008; 47: 718–723.

13. Ernste FC, Sanchez-Menendez M, Wilton KM, et al. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2015; 67 (7): 1015–1021.

14. Маркелова Е. И., Коротаева Т. В., Новикова Д. С. и др. Распространенность метаболического синдрома у больных псориатическим артритом: его связь с воспалением и субклиническим атеросклерозом. Научно-практическая ревматология. 2016; 54 (Прил. 1): 20–25.

15. Han C, Robinson D Jr, Hackett M et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006; 33: 2167–2172.

16. Gladman D, Ang M, Su L et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009; 68: 1131–5.

17. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardio-vascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2014; 74: 326–332.

18. Eder L, Thavaneswaran A, Chandran V et al. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis. 2015; 74: 1830–1835.

19. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007; 56: 2905–2912.

20. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011; 306: 864–871.

21. Labitigan M, Bahče-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014; 66: 600–607.

22. Johnsson H, McInnes IB, Sattar N. Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. Ann Rheum Dis. 2012; 71: 480–483.

23. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012; 51: 552–556.

24. Н. Н. Паньшина, Л. Н. Шилова. Клинические особенности метаболического синдрома у больных псориатическим артритом. Волгоградский научно-медицинский журнал. 2017; (1): 31–33.

25. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014; 41: 1357–1365.

26. Rossini M, Viapiana O, Adami S, et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels and correlated with parathyroid hormone, bone ero-sions and bone mineral density. Clin Exp Rheumatol. 2015; 33: 77–83.

27. Davey-Ranasinghe N, Deodhar A. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2013; 25: 509–516.

28. Adachi JD, Lau A. Systemic lupus erythematosus, osteoporosis, and fractures. J Rheumatol. 2014; 41: 1913–1915.

29. Maruotti N, Corrado A, Cantatore FP. Osteoporosis and rheumatic diseases. Reumatismo. 2014; 66: 125–135.

30. Grazio S, Cvijetić S, Vlak T, et al. Osteoporosis in psoriatic arthritis: is there any? Wien Klin Wochenschr. 2011; 123: 743–570.

31. Frediani B, Allegri A, Falsetti P, et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol. 2001; 28: 138–43

32. Gulati AM, et al. Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. RMD Open 2018; 4: e000631.

33. Haddad A, Cohen AD, Ashkenazi RI, et al. Endocrine comorbidities in patients with psoriatic arthritis — a population based case controlled study. J Rheumatol. 2017; 44 (6): 786–790.

34. Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatolю 2012; 53: 190–197.

35. Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with metho-trexate and/or leflunomide. Ann Rheum Dis. 2010; 69: 43–7.

36. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig. 2006; 26: 55–62.

37. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009; 51: 778–786.

38. Seitz M, Reichenbach S, Moller B, Zwahlen M, et al. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 2010; 69: 1148–1150.

39. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treat-ment. J Hepatol. 2007; 46: 1111–18.

40. Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014; 134: 1542–1551.

41. Rosenblat JD, Cha DS, Mansur RB, et al. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsy-chopharmacol Biol Psychiatry 2014; 53: 23–34.

42. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007; 21: 901–912.

43. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014; 41: 887–896.

44. Wu CY, Chang YT, Juan CK, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore). 2016; 95: e3816.

45. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013; 72: 1200–5.

46. Scarpa R, Manguso F, D'Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000; 27: 1241–1246.

47. Charlton R, et al. Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. Ann Rheum Dis. 2017; 0: 1–4.

48. Toussirot E, Houvenagel E, Goeb V, et al. Develop-ment of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine. 2012; 79: 457–463.

49. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000; 95: 1949–1954.

50. C. T. Ritchlin, R. A. Colbert, D. D. Gladman. Psoriatic Arthritis. N Engl J Med. 2017; 376: 957–970.

51. Geberg A, Khalid U, Gislason GH, et al. Association of psoriatic disease with uveitis: a danish nationwide cohort study. JAMA Dermatol. 2015; 151: 1200–1205.

52. Chi CC, Tung TH, Wang J, et al. Risk of uveitis among people with psoriasis: a nationwide cohort study. JAMA Ophthalmol. 2017; 135.

53. Brewerton DA, Caffrey M, Nicholls A, et al. Acute anterior uveitis and HL-A 27. Lancet. 1973; 302: 994–6.

54. Hou TY, Chen HC, Chen CH, et al. Usefulness of human leucocyte antigen-B 27 subtypes in predicting ankylosing spondylitis: Taiwan experience. Intern Med J. 2007; 37: 749–52

55. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996; 32A: 1753–1777.

56. Bernatsky S, Boivin J-F, Clarke A, et al. Cancer risk in systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 2001; 44 (Suppl 9): S 244.

57. Rosenthal AK, McLaughlin JK, Linet MS, et al. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis. 1993; 52: 531–533.

58. Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 2013; 65: 48–58.

59. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64: 1035–1050.

60. S. Bonovas, S Minozzi, T Lytras, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 2016; 15: 35–54.

61. Magrey MN, Antonelli M, James N, et al. High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study. Arthritis. 2013: 762921.

62. Brikman S, Furer V, Wollman J, et al. The effect of the presence of fibromyalgia on common clinical dis-ease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol. 2016; 43: 1749–54.

63. Y. El Miedany, M. El Gaafary, S. Youssef, et al. Psoriatic arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in psoriasis and psoriatic arthritis patients. Rheumatol Orthop Med. 2017; 2 (2): 1–7.

64. Higgins JPT, Greene S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011. [Accessed date]. Version 5.1.0 [updated March 2011]. handbook.cochrane.org.

65. Hшjgaard, P, Klokker, L, Orbai, A-M et al. A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism.2018; 47 (5): 654–665.

66. SP McKenna, L C Doward, D Whalley, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63: 162–169.

67. Leung YY, Thumboo J, Rouse M, et al. Adaptation of Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL) scale for use in Singapore. BMC Musculoskelet Disord. 2016: 17 (1): 432.

68. Madsen OR et al. Adaptation of the Psoriatic Arthritis Quality of Life (PsAQol) instrument for Sweden: comments on the article by Billing. Scand J Rheumatol. 2011 Jan; 40 (1): 80.


Для цитирования:


Файрушина И.Ф., Мухаметшина Э.И., Абдулганиева Д.И. Коморбидная патология и Patient Reported Outcomes при псориатическом артрите: обзор литературы. Медицинский алфавит. 2019;1(18):34-38. https://doi.org/10.33667/2078-5631-2019-1-18(393)-34-38

For citation:


Fairushina I.F., Abdulganieva D.I., Mukhametshina E.I. Comorbid pathology and patient reported outcomes in psoriatic arthritis: literature review. Medical alphabet. 2019;1(18):34-38. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-18(393)-34-38

Просмотров: 89


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)